CXCR2 and cystic fibrosis: In the present study, the in vivo pharmacology of a potent CXCR2 antagonist AZD8309 was evaluated in healthy human subjects using inhalation of LPS, a method which closely replicates key components of the inflammatory response associated with COPD, severe asthma and CF.